基本信息
views: 24
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research
The Janetka research laboratory is broadly interested in the X-ray structure-based drug design, medicinal chemistry and organic synthesis of chemical tools and small molecule drugs. In multiple drug discovery projects, we are developing inhibitors of proteases, kinases, lectins, and other protein targets for studying and treating cancer and a variety of infectious disease. One project is targeting several serine proteases including HGFA and hepsin which activate growth factors and cytokines in tumors. Another project is working on inhibitors of transmembrane serine proteases such as TMPRSS2 and matriptase as broad-spectrum antiviral drugs. We have a project focused on aspartic protease inhibitors and GPCR antagonists as novel therapy for River Blindness, caused by parasitic filarial worm infections. We are also working on phosphodiesterase inhibitors as well as inhibitors of PIM kinase and others as new anthelmintic drugs to treat intestinal worm infections caused by whipworm and hookworm. Further studies are directed on the rational design of CDPK1 kinase inhibitors as novel drugs to treat acute and cure chronic Toxoplasmosis. Finally, a large research effort is dedicated to the structure-guided design of glycomimetic lectin antagonists such as PapG as innovative antivirulence therapeutics for the treatment and prevention of bacterial infections and in one project targeting Fap2 for colon cancer.
The Janetka research laboratory is broadly interested in the X-ray structure-based drug design, medicinal chemistry and organic synthesis of chemical tools and small molecule drugs. In multiple drug discovery projects, we are developing inhibitors of proteases, kinases, lectins, and other protein targets for studying and treating cancer and a variety of infectious disease. One project is targeting several serine proteases including HGFA and hepsin which activate growth factors and cytokines in tumors. Another project is working on inhibitors of transmembrane serine proteases such as TMPRSS2 and matriptase as broad-spectrum antiviral drugs. We have a project focused on aspartic protease inhibitors and GPCR antagonists as novel therapy for River Blindness, caused by parasitic filarial worm infections. We are also working on phosphodiesterase inhibitors as well as inhibitors of PIM kinase and others as new anthelmintic drugs to treat intestinal worm infections caused by whipworm and hookworm. Further studies are directed on the rational design of CDPK1 kinase inhibitors as novel drugs to treat acute and cure chronic Toxoplasmosis. Finally, a large research effort is dedicated to the structure-guided design of glycomimetic lectin antagonists such as PapG as innovative antivirulence therapeutics for the treatment and prevention of bacterial infections and in one project targeting Fap2 for colon cancer.
Research Interests
Papers共 120 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ChemMedChemno. 8 (2024): e202300648-e202300648
Vivian Truong Jones,Ramona Graves-Deal,Zheng Cao,Galina Bogatcheva,Marisol A. Ramirez,Sarah J. Harmych,James N. Higginbotham, Claudia C. Wahoski, Neeraj Joshi,Joseph T. Roland,Gregory D. Ayers, Qi Liu,
Cancer Researchno. 6_Supplement (2024): 2001-2001
JOURNAL OF MEDICINAL CHEMISTRYno. 6 (2024): 4833-4854
Vivian Truong Jones,Ramona Graves-Deal,Zheng Cao,Galina Bogatcheva,Marisol A. Ramirez,Sarah J. Harmych,James N. Higginbotham, Vineeta Sharma,Vishnu C. Damalanka, Claudia C. Wahoski, Neeraj Joshi, Maria Johnson Irudayam,
Cancer letters (2023): 216286-216286
Cancer Researchno. 7_Supplement (2023): 2562-2562
Molecular oncologyno. 3 (2023): 547-561
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)
Load More
Author Statistics
#Papers: 124
#Citation: 4463
H-Index: 38
G-Index: 65
Sociability: 6
Diversity: 3
Activity: 22
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn